Pharmacist only category of medicines becoming a consumer backwater
5 May 2010 - Pharmacist-only category of medicines becoming a consumer backwater
The Australian Self-Medication Industry (ASMI), the industry body representing non-prescription consumer healthcare products today called for reforms to therapeutic goods regulation to allow a0dvertising for a growing category of consumer medicines.
The current prohibition on consumer advertising of certain medicines in the Pharmacist Only, or Schedule 3 (S3) category is short-changing consumers, and harming manufacturers who are unable to bring products to the notice of consumers who may benefit from them.
"It does not make sense to have a category of medicines that is available to the public, without prescription, but which is not able to be advertised to those who may need them," said the Executive Director of ASMI, Juliet Seifert.
"If these medicines are sufficiently safe to be allowed to be
sold without the need for a prescription, it also makes sense to
allow them to be responsibly advertised. "
Currently, therapeutic goods classified as S3 cannot be advertised unless they are included in Appendix H of the Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP).
Because these medicines can't be advertised and must be kept within the dispensary, consumers can often remain completely unaware of their existence. With no mechanism to expose consumers to the brand, many consumers do not find a need to speak to the pharmacist.
The S3 category now contains a range of medicines for conditions that can be safely managed with the intervention of a pharmacist including codeine combination analgesics, proton pump inhibitors, and treatments for eye infections and weight loss.
The situation is also damaging to the industry, with one major pharmaceutical firm required to restructure operations because its S3 product was not able to gain the advertising necessary to reach a broad-based consumer market. If the current restrictions remain, the S3 category without advertising will remain a backwater of little-known products that are largely uneconomic for providers.
The position is counter to that of the U.K. market where all
over-the-counter (OTC) products are able to be advertised direct to
consumers. One explanation for the advertising restriction in
Australia is that the possibility of inappropriate advertising
warrants certain S3 products being placed in a special
However, there are already safeguards over advertising of therapeutic products under the Therapeutic Goods Advertising Code which includes a process of pre-approvals, together with a complaints mechanism in the event of alleged breaches.
The other reason for the ban on advertising of some S3 products
is that advertising would lead to inappropriate patterns of use, an
assertion which has never been substantiated. "It'stime that the
advertising controls relevant to the Pharmacist Only category were
reviewed in light of recent scheduling decisions, and the need for
increased consumer awareness about latest treatment options.
"Without knowledge of the alternative treatments available, patients are more likely to have to visit an already overstretched GP for minor ailments, when an effective OTC remedy is available at a pharmacy," Ms Seifert said.
About ASMI: The Australian Self-Medication Industry (ASMI) is the peak industry body for the Australian self care industry representing consumer healthcare products including over-the-counter medicines and complementary medicines. ASMI's mission is to promote better health through responsible self-care. This
means ensuring that safe and effective self-care products are readily available to all Australians at a reasonable cost. ASMI works to encourage responsible use by consumers and an increasing role for cost-effective selfmedication
products as part of the broad national health strategy. www.asmi.com.au
Media contact: Bob Bowden, Foresight Communications (02) 9241 2811, 0412 753 298